See Graham's ranking
4.0
Danaher Corporation operates within the healthcare and technology sectors, with activities in the life sciences, diagnostics and laboratory equipment subsectors. Its shares are traded on the New York Stock Exchange (NYSE) under the ticker DHR. The company was founded by Steven and Mitchell Rales, driven by the objective of building an industrial conglomerate focused on continuous innovation and operational excellence grounded in standardized management systems.
Its core products and services include clinical diagnostic systems, laboratory instruments, bioprocessing solutions, molecular analysis technologies, precision measurement tools, scientific research equipment and platforms used in the manufacturing of biological therapies. These offerings serve hospitals, laboratories, biopharmaceutical manufacturers, universities and research institutions.
Danaher’s addressable market is global, with commercial presence in North America, Europe, Asia-Pacific, the Middle East and Latin America. Operations support demand across healthcare, pharmaceuticals, biotechnology, industrial monitoring and scientific research, with established market share in countries such as the United States, Germany, the United Kingdom, China and Japan.
Relevant market drivers include rising demand for advanced clinical diagnostics, expansion of the biopharmaceutical industry, increasing need for automated laboratory solutions, higher R&D investments, stringent healthcare regulatory standards and competition from global manufacturers of laboratory equipment and consumables. Technological trends such as continuous bioprocessing, laboratory digitalization and biological therapy development shape the company’s innovation and growth strategy.
Danaher’s operational scale includes tens of thousands of employees, hundreds of manufacturing sites and research facilities, and thousands of corporate and institutional clients. Its activities span global production of equipment, technical support services, integration of laboratory platforms and international distribution.
The company’s operating structure comprises its headquarters in Washington, D.C., divisions dedicated to diagnostics, life sciences and environmental solutions, manufacturing hubs across multiple countries, biotechnology research units and innovation laboratories. Logistics rely on complex supply chains, industrial technology integration and global service coverage for corporate clients.
Danaher’s operating model is built on the Danaher Business System (DBS), a proprietary framework for continuous improvement, operational efficiency, process standardization and data-driven innovation. Core practices include lean management, digital integration, total quality programs and specialized technical support. The primary trading ticker is DHR on the NYSE.
History and Foundation
Danaher was founded in 1984 in Washington, D.C., with the objective of consolidating a diversified industrial group built on efficient operating processes and a portfolio centered on high-precision technologies.In its early years, the company faced challenges related to expanding its portfolio through strategic acquisitions, implementing the DBS operating system and strengthening synergies across business units. Initial achievements included reinforcing its industrial divisions and gaining operational scale.
A subsequent expansion cycle was driven by entry into clinical diagnostics, life sciences and health-technology segments through acquisitions of leading companies in biotechnology, bioanalytics and laboratory solutions. This period also marked broader geographic reach, with operations and customers across both developed and emerging markets.
Historical milestones include its 1984 initial public offering (IPO) and major acquisitions such as Leica Microsystems (2005), Beckman Coulter (2011) and Pall Corporation (2015). Other key events include the spinoff of Fortive Corporation in 2016 and the separation of Veralto Corporation in 2023, reshaping the strategic portfolio toward healthcare and life sciences.
Between 2020 and 2024, relevant developments included rising global demand for diagnostics and laboratory solutions, expansion in bioprocessing operations, investments in technologies supporting biological therapy production, adjustments to the corporate structure following strategic reorganizations and ongoing evolution of the company’s competitive position within the global life sciences market. These factors influenced operational performance and business dynamics throughout the period.
Additional Information
The Company Danaher Corporation (United States), is listed on NYSE with a market value of $ 163.81 Billions, having an equity of $ 51.08 Billions.
With a total of 80.000 employees, the company is listed in the sector of Health and categorized in industry of Life Science Tools and Services.
In the last 12 months the Company had a revenue of $ 24.27 Billions, which generated a profit in the amount of $ 3.50 Billions.
As for its main indicators, the Company has a P/E ratio of 46.76, a P/BV ratio of 3.21 and in the last 12 months the dividend yield of DHR was at 0.53%.
The Company is traded internationally through the ticker DHR.
